Background: Sequential therapy is used as an alternative to growing antibiotic resistance of Helicobacter pylori to the standard triple therapy. Despite the success it had in Europe, we have no information regarding this therapy in our region.
Objectives: To evaluate the eradication rate of Helicobacter pylori using sequential therapy and show its adverse effects.
Methods: We performed a prospective, observational, open descriptive study. 31 patients were evaluated who were treated with sequential therapy in the following way: the first 5 days omeprazole 20 mg and amoxicillin 1 g every 12 hours and following 5 days omeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg every 12 hours. After four weeks of treatment, each patient had a C13 urea breath test to check for eradication.
Results: 31 patients were included, one patient was excluded from the protocol due to adverse drug react to amoxicillin. Of the remaining 30 patients who completed treatment, 22 (73%) were negative to breath test and 8 (27%) were positive. Of the patients who completed treatment, 10 had minor adverse events to treatment, the main symptoms were epigastralgia and nausea.
Conclusions: Sequential therapy had an eradication rate of 73% which is much lower than that reported in European studies. However, therapy is easily accesible with lower cost and fewer side effects tan standard therapy.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Emergency Department, The State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Variation in the incidence, survival rate and factors associated with survival after cardiac arrest in China is reported. Some studies have tried to fill the knowledge gap regarding the epidemiology of cardiac arrest in China but were unable to identify reasons for the reported differences. Therefore, the purpose of this study was to describe Chinese management of cardiac arrest, particularly from the perspective of compression, ventilation, monitoring, treatment, and extracorporeal cardiopulmonary resuscitation.
View Article and Find Full Text PDFLeukemia
January 2025
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
CRCL, Centre Léon Bérard, Lyon, France.
Publicly available trial matching tools can improve the access to therapeutic innovations, but errors may expose to over-solicitation and disappointment. We performed a pragmatic non-interventional prospective evaluation on sequential patients at the Molecular Tumor Board of Centre Leon Berard. During 10 weeks in 2024, we analysed 157 patients with four clinical trial matching tools from the 19 screened: Klineo, ScreenAct, Trialing and DigitalECMT.
View Article and Find Full Text PDFJMIR Res Protoc
January 2025
McMaster University, Hamilton, ON, Canada.
Background: Research has shown that engaging in a range of healthy lifestyles or behavioral factors can help reduce the risk of developing dementia. Improved knowledge of modifiable risk factors for dementia may help engage people to reduce their risk, with beneficial impacts on individual and public health. Moreover, many guidelines emphasize the importance of providing education and web-based resources for dementia prevention.
View Article and Find Full Text PDFMelanoma Manag
December 2024
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Latina, Italy.
Aims: In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.
Patients And Methods: We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.
Results: A total of 88 patients diagnosed with melanoma were identified.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!